Table 4 Cox regression analyses of mAge acceleration versus mortality in schizophrenia and controls after excluding individuals with pre-existing cancer

From: Methylation age acceleration does not predict mortality in schizophrenia

 

SCZ-died (n = 83) vs. SCZ-alive (n = 56)

SCZ-died (n = 83) vs. Controls-alive (n = 56)

SCZ-died (n = 83) vs. Controls-died (n = 53)

 

Unadjusted

Adjusteda

Unadjusted

Adjusteda

Unadjusted

Adjusteda

Hannum

1.06 (0.98–1.14); p = 0.09

1.13 (1.04–1.22); p = 0.005

1.04 (0.97–1.10); p = 0.27

1.10 (1.01–1.19); p = 0.02

1.03 (0.99–1.08); p = 0.18

1.05 (0.98–1.11); p = 0.12

Horvath

1.04 (0.97–1.10); p = 0.28

1.06 (0.99–1.13); p = 0.08

1.00 (0.95–1.07); p = 0.89

1.06 (0.99–1.14); p = 0.08

1.00 (0.96–1.04); p = 0.96

1.01 (0.97–1.06); p = 0.55

Levine

1.01 (0.97–1.07); p = 0.44

1.01 (0.96–1.07); p = 0.63

1.03 (0.98–1.08); p = 0.25

0.99 (0.94–1.05); p = 0.76

0.99 (0.96–1.04); p = 0.91

0.98 (0.94–1.03); p = 0.56

  1. Values are Hazard Ratios (95% Confidence Intervals) and p-values
  2. aAdjusted for white blood cell counts, age, sex, smoking score, and methylation batch
Back to article page